Placebo News and Research

RSS

AbbVie's global sales reduce 1.8% to $5.111B in fourth quarter 2013

AbbVie today announced financial results for the fourth quarter and full year ended Dec. 31, 2013.

31 Jan 2014

Children with peanut allergies could benefit from oral immunotherapy treatment

Children and adolescents with peanut allergies could benefit from treatment with oral immunotherapy (OIT), in which peanut protein is consumed in increasingly larger amounts on a regular basis to build up tolerance, according to a phase 2 trial published in The Lancet.

31 Jan 2014

Alexion Pharmaceuticals reports full year 2013 GAAP and non-GAAP financial results

Alexion Pharmaceuticals, Inc. today announced financial results for the quarter and year ended December 31, 2013. For the three months ended December 31, 2013, Alexion Pharmaceuticals, Inc. ("Alexion" or the "Company") reported net product sales of Soliris® (eculizumab) of $441.9 million, compared to $320.5 million for the same period in 2012.

30 Jan 2014

AVEO Oncology, Astellas Pharma decide to discontinue BATON breast cancer clinical trial

AVEO Oncology today announced that AVEO and Astellas Pharma Inc. have jointly decided to discontinue the BATON (Biomarker Assessment of Tivozanib in ONcology) breast cancer clinical trial, a Phase 2 study in patients with locally recurrent or metastatic triple negative breast cancer (TNBC), due to insufficient enrollment.

30 Jan 2014

Oramed Pharmaceuticals' ORMD-0801 Phase 2a study meets primary and secondary endpoints

Oramed Pharmaceuticals Inc., a developer of oral drug delivery systems, announced today results from its Phase 2a clinical trial for its ORMD-0801 oral insulin capsule for the treatment of type 2 diabetes. The trial was conducted under a United States Food and Drug Administration IND (Investigational New Drug) protocol. The Phase 2a study met all primary and secondary endpoints.

30 Jan 2014

Omeros announces positive results from Phase 2a trial of OMS824 in patients with schizophrenia

Omeros Corporation today announced positive results from a Phase 2a clinical trial of OMS824, the company's phosphodiesterase 10 (PDE10) inhibitor, in which the drug was well tolerated and demonstrated comparable systemic pharmacokinetics when administered alone and concomitantly with approved antipsychotic agents in patients with schizophrenia. OMS824 selectively inhibits PDE10, an enzyme expressed in areas of the brain linked to a wide range of diseases that affect cognition, including schizophrenia and Huntington's disease.

29 Jan 2014

Consumption of probiotics could help promote healthy weight in women, says study

Certain probiotics could help women lose weight and keep it off, according to a recent study published in the British Journal of Nutrition by a team of researchers headed by Universit- Laval Professor Angelo Tremblay.

29 Jan 2014

Anxiety, depression and meditation: an interview with Dr Madhav Goyal, Johns Hopkins University School of Medicine

We wanted to be broadly inclusive of any kind of meditation program, so we defined a meditation program to be any kind of structured meditation program that involved at a minimum 4 hours of training, with instructions to practice outside the classroom.

28 Jan 2014

Top-line results from two Phase 3 studies of dacomitinib for patients with advanced NSCLC published

Pfizer Inc. today announced top-line results from two randomized Phase 3 studies of the irreversible pan-HER kinase inhibitor dacomitinib in patients with advanced non-small cell lung cancer.

28 Jan 2014

Study shows taking vitamin D2 supplements may result in higher muscle damage in athletes

Power athletes and others looking for an edge to improve their performance should avoid taking vitamin D2.

28 Jan 2014

Scientists start clinical trial of EDP-788 oral antibiotic to treat MRSA infections

Scientists have begun the first human clinical trial of EDP-788, an investigational oral antibiotic intended to treat methicillin-resistant Staphylococcus aureus (MRSA) infections.

27 Jan 2014

S. pneumoniae predicts acute sinusitis microbial response

Research from the USA shows that confirmed nasopharyngeal colonization with Streptococcus pneumoniae independently predicts a rapid response to antimicrobial therapy in children with acute sinusitis.

27 Jan 2014

Immunotherapy maintenance shows promise in NSCLC

Results from a phase III trial have shown that tecemotide is no more effective than placebo as maintenance therapy in patients with non-small-cell lung cancer.

24 Jan 2014

TherapeuticsMD starts TX 12-002-HR phase 3 clinical trial for secondary amenorrhea

TherapeuticsMD, Inc., a women's healthcare company, announced today that it has initiated the SPRY Trial, a randomized, placebo-controlled phase 3 clinical trial designed to evaluate the safety and efficacy of TX 12-002-HR, its oral progesterone candidate for secondary amenorrhea, a condition treated to maintain fertility in young premenopausal women.

24 Jan 2014

Pfizer announces results from Phase 3 study of ALO-02 in patients with chronic low back pain

Pfizer Inc. (NYSE: PFE) announced today top-line results from a Phase 3 study of investigational agent ALO-02 (oxycodone hydrochloride and naltrexone hydrochloride extended-release capsules) in patients with moderate-to-severe chronic low back pain.

24 Jan 2014

Use of twice-daily pill could turn deadly blood cancer into highly treatable disease

Use of a twice-daily pill could turn a deadly blood cancer into a highly treatable disease, according to scientists at Weill Cornell Medical College who led a multinational research team.

24 Jan 2014

Prosonix announces positive top-line results from PSX1002 Phase 2 study for COPD treatment

Prosonix, an innovative speciality pharmaceutical company developing a portfolio of inhaled Respiratory Medicines by Design, announces positive top-line results from its Phase 2 clinical study with PSX1002 in patients with moderate to severe chronic obstructive pulmonary disease.

23 Jan 2014

New drug helps children and young adults who have severe pain from sickle cell disease

Saint Louis University researchers are studying whether ReoPro® (abciximab), a drug currently given to heart patients undergoing angioplasties to open blocked arteries, also could help children and young adults who have severe pain from sickle cell disease.

23 Jan 2014

Hydroxytyrosol in olive oil may help reduce risk of breast cancer

A major component of olive oil, hydroxytyrosol, is the subject of a Houston Methodist study of women who are at increased risk of developing breast cancer. The study focuses on the changes in breast density after one year of treatment and is the first of its kind in the United States.

23 Jan 2014

EnVivo Pharmaceuticals starts encenicline Phase 3 study in patients with Alzheimer's disease

EnVivo Pharmaceuticals, a company dedicated to developing a broad range of novel therapies for central nervous system diseases, today announced it has initiated COGNITIV AD, a Phase 3 clinical program evaluating its novel alpha-7 (α7) potentiator, encenicline-hydrochloride (EVP-6124), in patients with Alzheimer's disease. The program is being conducted under a Special Protocol Assessment agreement with the FDA.

22 Jan 2014

Placebo News and Research

AbbVie's global sales reduce 1.8% to $5.111B in fourth quarter 2013

Children with peanut allergies could benefit from oral immunotherapy treatment

Alexion Pharmaceuticals reports full year 2013 GAAP and non-GAAP financial results

AVEO Oncology, Astellas Pharma decide to discontinue BATON breast cancer clinical trial

Oramed Pharmaceuticals' ORMD-0801 Phase 2a study meets primary and secondary endpoints

Omeros announces positive results from Phase 2a trial of OMS824 in patients with schizophrenia

Consumption of probiotics could help promote healthy weight in women, says study

Anxiety, depression and meditation: an interview with Dr Madhav Goyal, Johns Hopkins University School of Medicine

Top-line results from two Phase 3 studies of dacomitinib for patients with advanced NSCLC published

Study shows taking vitamin D2 supplements may result in higher muscle damage in athletes

Scientists start clinical trial of EDP-788 oral antibiotic to treat MRSA infections

S. pneumoniae predicts acute sinusitis microbial response

Immunotherapy maintenance shows promise in NSCLC

TherapeuticsMD starts TX 12-002-HR phase 3 clinical trial for secondary amenorrhea

Pfizer announces results from Phase 3 study of ALO-02 in patients with chronic low back pain

Use of twice-daily pill could turn deadly blood cancer into highly treatable disease

Prosonix announces positive top-line results from PSX1002 Phase 2 study for COPD treatment

New drug helps children and young adults who have severe pain from sickle cell disease

Hydroxytyrosol in olive oil may help reduce risk of breast cancer

EnVivo Pharmaceuticals starts encenicline Phase 3 study in patients with Alzheimer's disease

Exploring the G:Box and for high-quality imaging

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Latest News